Alexander Kamb

Company: A2 Biotherapeutics Inc.

Job title: Chief Scientific Officer

Seminars:

A Cell Therapy that Targets Gene Loss with a Logic-Gate to Differentiate Between Normal and Tumor Cells 2:00 pm

The problem: Targeting cell therapies to solid tumors The solution: Engineering a dual signal-integration mechanism (Tmod) that exploits loss of heterozygosity to distinguish between normal and tumor cells The evidence: in vitro and in vivo studies with CEA and MSLN to support safety and efficacy for a Tmod logicgated cell therapy The platform can be…Read more

day: Day 1 - Track A - Lunch